Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2001
Business Overview: Stryker operates in two primary segments: Orthopaedic Implants (reconstructive and trauma products) and MedSurg Equipment (surgical instruments, imaging, and patient care equipment). The company also reports Physical Therapy Services and corporate administration under "Other."
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 | Three Months Ended June 30, 2001 | Three Months Ended June 30, 2000 |
|---|---|---|---|---|
| Net Sales ($ millions) | $1,273.2 | $1,128.6 | $639.0 | $566.5 |
| Gross Profit ($ millions) | $803.6 | $724.0 | $401.7 | $363.5 |
| Gross Margin (%) | 63.1% | 64.2% | 62.9% | 64.2% |
| Net Earnings ($ millions) | $129.8 | $104.5 | $65.7 | $52.7 |
| Diluted EPS ($) | $0.64 | $0.52 | $0.32 | $0.26 |
| Operating Cash Flow ($ millions) | $152.0 | $109.5 | N/A | N/A |
| Total Debt ($ millions) | $883.6 | N/A | N/A | N/A |
| Cash and Equivalents ($ millions) | $42.6 | N/A | N/A | N/A |
Liquidity: Working capital increased to $409.3 million. The company maintains $248.3 million in additional borrowing capacity under existing credit facilities.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year for both the quarter and the six-month period. Growth was driven by a 12% increase in unit volume and higher selling prices, partially offset by a 3-4% negative impact from foreign currency exchange rates.
- Segment Performance:
- Domestic Sales: Increased 21% (six months) and 22% (quarter) due to strong shipments in Orthopaedic Implants and MedSurg Equipment.
- International Sales: Increased 1% (six months) but declined 2% (quarter) due to unfavorable currency rates. Excluding currency, international sales grew 9% and 7% respectively.
- Product Lines: MedSurg Equipment sales grew 19-20%, Orthopaedic Implants grew 7%, and Physical Therapy Services grew 28-29%.
- Profitability: Net earnings rose 24% (six months) and 25% (quarter). The effective tax rate decreased to 33.0% from 34.0% due to manufacturing tax benefits in Ireland and Puerto Rico.
- Cost Structure: Cost of sales as a percentage of sales increased slightly (36.9% vs 35.8% for six months) primarily due to a change in accounting for freight revenue and shipping costs, which were reclassified from SG&A to Cost of Sales.
- Debt Reduction: Total debt declined by $128.9 million during the first half of 2001, with interest expense dropping significantly ($36.3 million vs $52.2 million for six months).
Guidance, Outlook, and Risks
- Accounting Changes: The FASB approved Statements No. 141 and 142 regarding business combinations and goodwill. Effective January 1, 2002, Stryker will cease amortizing goodwill. This is expected to reduce intangibles amortization by approximately $15 million and increase net earnings by $10 million ($0.05 per diluted share) in 2002. Initial impairment tests will be performed in 2002.
- New Product Launches: The OP-1 Implant received marketing approval in Australia and the EU. Commercial sales began in Australia in mid-May 2001, with EU launch expected in Q3 2001. Management does not anticipate a significant sales impact in 2001.
- Restructuring: Remaining headcount reductions from prior acquisition-related restructuring are expected to be completed in 2001. Final payments for the Howmedica acquisition working capital adjustment ($27.2 million) were made in Q3 2001.
- Risks: Forward-looking statements are subject to risks including changes in economic conditions, foreign exchange markets, financial markets, and competitive environments. Unhedged international net assets are subject to translation losses (e.g., $40.0 million loss in the first half of 2001).
Investor Verification Checklist
- Currency Impact: Verify the extent to which foreign exchange rates suppressed international revenue growth, as organic growth was significantly higher than reported.
- Accounting Reclassification: Confirm the impact of reclassifying freight revenue and shipping costs on gross margin and SG&A comparisons with prior years.
- Debt Maturities: Review the schedule of debt maturities, noting current maturities of $138.4 million and projected increases to $175.5 million and $213.9 million for the twelve months ending June 30, 2003 and 2004.
- Goodwill Impairment: Monitor the 2002 initial impairment tests for goodwill and indefinite-lived intangible assets, as the outcome is currently undetermined.
- Howmedica Liabilities: Track the completion of remaining distributor conversion and severance obligations related to the 1998 Howmedica acquisition.